Maintenance therapy with the common macrolide antibiotic azithromycin halves the rate of respiratory events in patients with primary ciliary dyskinesia (PCD) – otherwise known as immotile-cilia syndrome – in the first multicentre randomized controlled clinical trial of azithromycin in PCD.
A maintenance regimen comprising olaparib and bevacizumab led to greater progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, results of the phase III PAOLA-1/ENGOT-ov25* study showed.
Use of statins appears to reduce the risk of developing hepatocellular carcinoma in patients with nonalcoholic fattly liver disease (NAFLD), whereas hypertension conferred a risk increase, according to a retrospective case-control study.
Men with metastatic castration-resistant prostate cancer (mCRPC) derived significantly greater clinical benefit from cabazitaxel vs the androgen receptor-targeted agents (ARTA) abiraterone or enzalutamide, according to the results of the CARD* trial presented at ESMO 2019.
Subgroup analyses of the GLOBAL LEADERS study showed similar treatment effects between ticagrelor and aspirin monotherapy following percutaneous coronary intervention (PCI) in patients with impaired renal function (IRF)* and diabetes.
Dupilumab significantly improves all disease components of severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP) — a primarily type 2 inflammatory condition — compared with placebo when both are added to standard of care. Furthermore, the treatment benefit extends to even patients with comorbid nonsteroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD), according to a pooled analysis of the LIBERTY NP SINUS-24 and -52* trials presented at ERS 2019.
The use of tumour necrosis factor-α (TNFα) inhibitors was not associated with an increased risk of infection in children with inflammatory bowel disease (IBD), a contrast to previous findings in adult IBD, a study from Denmark showed.
The use of degludec in insulin-naïve patients with type 2 diabetes (T2D) appears to reduce HbA1c levels with a lower risk of hypoglycaemia, based on real-world data from the CONFIRM* trial presented at EASD 2018.
The selective β3-adrenoreceptor (AR) agonist vibegron showed superior efficacy over placebo for overactive bladder (OAB) treatment and was generally well-tolerated, according to a Japanese study presented at EAU 2018.
A combination of tocilizumab and methotrexate reduced disease activity at 2 years compared with methotrexate plus prednisone in patients with early rheumatoid arthritis (RA), an effect not demonstrated with tocilizumab monotherapy.
The anticholinergic agent oxybutynin significantly reduces the intensity and frequency of hot flushes among women in whom hormone replacement therapy was contraindicated such as breast cancer survivors, according to the ACCRU study SC-1603 presented at SABCS 2018.